Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.

doi:10.1093/neuonc/noac207

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.

Neuro-oncology - 5 Jan 2023

Miller Julie J, Gonzalez Castro L Nicolas, McBrayer Samuel, Weller Michael, Cloughesy Timothy, Portnow Jana, Andronesi Ovidiu, Barnholtz-Sloan Jill S, Baumert Brigitta G, Berger Mitchell S, Bi Wenya Linda, Bindra Ranjit, Cahill Daniel P, Chang Susan M, Costello Joseph F, Horbinski Craig, Huang Raymond Y, Jenkins Robert B, Ligon Keith L, Mellinghoff Ingo K, Nabors L Burt, Platten Michael, Reardon David A, Shi Diana D, Schiff David, Wick Wolfgang, Yan Hai, von Deimling Andreas, van den Bent Martin, Kaelin William G, Wen Patrick Y

Abstract excerpt

Isocitrate dehydrogenase (IDH) mutant gliomas are the most common adult, malignant primary brain tumors diagnosed in patients younger than 50, constituting an important cause of morbidity and mortality. In recent years, there has been significant progress in understanding the molecular pathogenesis and biology of these tumors, sparking multiple efforts to improve their diagnosis and treatment. In this consensus...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Metastases and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Brain Neoplasms

Share to Consensus

Share to Glioma

Share to Glioma Diagnosis and Treatment

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Neuroblastoma Research and Treatments

Source

Open in PubMed Open full text

Identifiers

PMID: 36239925
DOI: 10.1093/neuonc/noac207
PMCID: PMC9825337

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.PMID 36239925Read ↗

Therapies for IDH-Mutant Gliomas.Semantic proximity Read ↗

IDH mutant high-grade gliomasSemantic proximity Read ↗

Updates on the WHO diagnosis of IDH-mutant glioma.Semantic proximity Read ↗

Management of Adult Patients With Isocitrate Dehydrogenase-Mutant Gliomas in Australia: An Expert Position Statement From the Cooperative Trials Group for Neuro-Oncology.Semantic proximity Read ↗

State of the Art in Low-Grade Glioma Management: Insights From Isocitrate Dehydrogenase and Beyond.Semantic proximity Read ↗

A review of adult-type diffuse gliomas in the WHO CNS5 classification with special reference to Astrocytoma, IDH-mutant and Oligodendroglioma, IDH-mutant and 1p/19q codeleted.Semantic proximity Read ↗

Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.Semantic proximity Read ↗

Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastomaSemantic proximity Read ↗

Management for Different Glioma Subtypes: Are All Low-Grade Gliomas Created Equal?Semantic proximity Read ↗

Current and promising treatment strategies in glioma.Semantic proximity Read ↗

IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical ImplicationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.